New to the RAP threads, only 10 trading days left in August for trial results, last time was a disaster but we can learn a lot from them.
Market is pricing in about half the likelihood that the trials pass of what it had last time, 20c compared to 40ish last time. IMO the Lockheed Martin should cause for a larger amount being priced in but can understand the concern after last time.
It is good to see how well the board has managed their money and kept pushing through to the second round of trials off the negativity and stock price slaughter last time, theyve kept their story that it was due to poor sound sampling and already treated patients consistent so is obvious they truly believe in the product, hopefully RAP gets the results they want this time around! GLTAH
Ann: ResApp Partners with Lockheed Martin for DARPA Research, page-106
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
